Lakefront Biotherapeutics (LKFT) Change in Cash (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Change in Cash for 11 consecutive years, with -$25.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash fell 153.68% year-over-year to -$25.5 million; the TTM figure through Mar 2026 stood at -$44.2 million (down 223.43% YoY), while the FY2025 annual figure was $32.7 million, up 129.32% from the prior year.
• Change in Cash retreated to -$25.5 million in Q1 2026 per LKFT's latest filing, from $28.8 million in the prior quarter.
• Across five years, Change in Cash topped out at $47.5 million in Q1 2025 and bottomed at -$1.1 billion in Q1 2022.
• Historically, Change in Cash has averaged -$138.3 million across 5 years, with a median of -$17.9 million in 2024.
• On a YoY basis, Change in Cash climbed as much as 265.08% in 2025 and fell as far as 2356.01% in 2025.
• Lakefront Biotherapeutics' Change in Cash stood at -$167.0 million in 2022, then soared by 105.38% to $9.0 million in 2023, then fell by 12.15% to $7.9 million in 2024, then soared by 265.08% to $28.8 million in 2025, then tumbled by 188.41% to -$25.5 million in 2026.
• Business Quant data shows LKFT's Change in Cash at -$25.5 million in Q1 2026, $28.8 million in Q4 2025, and -$8.3 million in Q3 2025.